Radium-223 is the 5th treatment for metastasized castration resistant prostate cancer with a proven overall survival benefit. The improved survival of Radium-223 over placebo was demonstrated in the ALSYMPCA trial, which included a miscellaneous…
ID
Bron
Verkorte titel
Aandoening
Radium-223; prostate cancer
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
1.To evaluate the efficacy of Radium-223 treatment in a non-study population by effects on Symptomatic Skeletal Event (SSE)<br>
2. Evaluate Radium-223 treatment efficacy by patient reported analgesic use and pain outcome
Doel van het onderzoek
Radium-223 is the 5th treatment for metastasized castration resistant prostate cancer with a proven overall survival benefit. The improved survival of Radium-223 over placebo was demonstrated in the ALSYMPCA trial, which included a miscellaneous patient population both docetaxel pretreated and non-pretreated. This registry aims to describe non-study patients treated with Radium-223 and prospectively evaluate treatment outcomes of patients with and without docetaxel pretreatment. Analgesic use and patient reported pain scores, efficacy of the subsequent therapy and overall survival will be evaluated. Moreover, clinical and explorative serum and blood biomarkers of Radium-223 efficacy will be explored.
Onderzoeksopzet
Every participating hospital will be visited for data entry at least annually.
Onderzoeksproduct en/of interventie
This registry aims to evaluate the efficacy of Radium-223 treatment in a non-study population of CRPC patients treated earlier with Docetaxel and patients not treated earlier with Docetaxel and efficacy of the first subsequent therapy.
The registry only dictates the collection of base line characteristics, expansion of regular blood tests and patient reported pain scores.
Publiek
S.K. Badrising
Plesmanlaan 121
Amsterdam 1066CX
The Netherlands
s.badrising@nki.nl
Wetenschappelijk
S.K. Badrising
Plesmanlaan 121
Amsterdam 1066CX
The Netherlands
s.badrising@nki.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. At the physicians discretion
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. At the physicians discretion
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL4734 |
NTR-old | NTR5075 |
Ander register | PTC14.103 : ROTOR |